Yes, Dysport has been clinically demonstrated up to 5 months. 1-3*  In 3 clinical studies of people whose between the brow frown lines were rated “moderate” or “severe” by a specialist before their treatment with Dysport 4*: 30 days after treatment, a majority of Dysport users† (55%, 52% and 60% in each of the 3 studies vs. 0% of users treated with placebo) and their specialists both thought their frown lines improved by at least 2 grades to a rating of “none” or “mild” at maximum frown. 30 days after treatment, the majority of Dysport users (88%, 85% and 86% in each of the 3 studies vs. 4%, 4% and 0%, respectively, of users treated with placebo) had their frown lines rated by a specialist as “none” or “mild” with at least a 1-grade improvement at maximum frown. 30 days after treatment, the majority of Dysport users (74%, 79% and 82% in each of the 3 studies vs. 9%, 1% and 2%, respectively, of users treated with placebo) rated their own frown lines as “none” or “mild” with at least a 1-grade improvement at maximum frown. Dysport is used in 69 countries around the world. 5* Ask your specialist if prescription Dysport is right for you. Dysport may not be right for you if: you have surgical changes to your face, very weak muscles in the treatment area, your face looks very different from side to side, the injection site is inflamed, you have droopy eyelids or sagging eyelid folds, deep facial scars, thick oily skin, or if your wrinkles can’t be smoothed by spreading them apart. See below for Dysport Important Safety Information and Medication Guide. *GL-1 and GL-3 evaluated subjects for at least 150 days following treatment. Based on a ≥1-Grade GLSS improvement from baseline utilizing data from two double-blinded, randomized, placebo-controlled pivotal studies (GL-1, GL-3) in a post-hoc analysis. †User = Clinical trial subject. References Data on file. GL-Y-97-52120-719 (GL-1) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007. Data on file. GL-Y-97-52120-718 (GL-3) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007. Data on file. MA-35497. Post Hoc Analysis. Fort Worth, TX: Galderma Laboratories, L.P., 2017. Dysport for Injection Package Insert. Fort Worth, TX: Galderma Laboratories, L.P.; January 2019. Data on file. Ipsen World-Wide Marketing Authorisation Status. Fort Worth, TX: Galderma Laboratories, L.P., February 2017.